NTSAD

SAM PARKER Chief Patient Access Officer

APRIL 12, 2019





NTSAD Family Conference, 2019

1

...HOW IT ALL STARTED...

LYSQ

Lysogene Today: Focus in Orphan CNS Diseases


				DEVELOPMENT STAGE				
INDICATION	PROGRAM	VECTOR	ENZYME	POC	PRE-CLINICAL	PHASE 1/2*	PIVOTAL	COMMENTS
Sanfilippo A (MPS IIIA)	LYS-SAF302	AAVrh10	N-sulfoglycosamine sulphohydrolase					PIVOTAL TRIAL START H2 2018 (FPI**)
GM1 Gangliosidosis			Beta-galactosidase-1					Phase 1/2 trial IND submission
Fragile X syndrome (FXS)	FXS01	AAV	5'-truncated Diacylglycerol Kinase Kappa (Dgkk)					Pre-clinical proof of concept

*MPS IIIA Phase 1/2: LYS-SAF301, first generation program ** FPI : « First Patient In »: First Patient Enrolled



3

Intra-CSF administration: Preferred RoA for indications with CNS including spinal cord & cerebellum involvement



- A single therapy is anticipated to compensate for the genetic abnormality
- The goal of therapy is a steady state, rather than varying levels of the therapy over time as with recombinant protein therapy

LYSOGENE

Gene therapy for GM1 Gangliosidosis

GM1 Gangliosidosis

GM1 gangliosidosis disease is caused by the absence or significantly reduced level of the enzyme beta-galactosidase (GLB1).

Severe GM-1 ganglioside build up causes progressive neurodegeneration.

The later onset forms of GM1 occur when the mutations allow the GLB1 enzyme to function a little bit.


Just a small increase in GLB1 activity is enough to delay the onset and slow the progression of symptoms. Project: LYS-GM101

Mechanism of action:

Replacement of β gal, reducing GM1 ganglioside accumulation

GLB1 gene AAVrh10 vector

Administration route



Special regulatory status:

Orphan Drug Designation – FDA Rare Pediatric Disease Designation

LYSOGENE

AAVrh.10 β gal corrects lysosomal pathology in GM1 animal models



AAVrh.10 β gal treatment of GM1 mice and GM1 cats:

- Significantly increases βgal activity in the brain and reduces lysosomal storage throughout CNS compartments
- Produces long-term βgal expression

In addition, have shown that LYS-SAF302 yields broad distribution of SGSH enzyme activity in brain, cerebellum and spinal cord of non-human primate

GM1 GANGLIOSIDOSIS LYS-GM101: Anticipated adaptive Study Design

narily look at speech and motor history data, potentially serving as external control, already published oing
patients
:hs follow-up
lEurope
3 L

Responsibility and Parpose

- Create and work beside global networks of patients, experts, clinicians, policy makers and regulators
- Patient centric : create therapies that will offer a better life for patients

YSOGENE

We thank the children, their parents and families for their continued contribution, time and energy to progressing research in finding treatments

LYSOGENE

SAM PARKER